ACTRIMS 2020: Post-Conference Perspectives
Investigators caution health care providers to consider specific risks of severe COVID-19 infection before initiating this therapy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup
2
FDA Clears Phase 2 Trial for Demyelinating Agent Lucid-MS in Progressive Multiple Sclerosis
3
Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis
4
Zoster Vaccine Shows Strong Effectiveness in Patients With Multiple Sclerosis
5